Table 1.
ICIs | Trade Name | Date of Approval | Drug-Dose |
---|---|---|---|
Pembrolizumab | Keytruda | July 2018 | 200mg |
Nivolumab | Opdivo | June 2018 | 240mg |
Toripalimab | TuoYi | December 2018 | 240mg |
Sintilimab | Daboshu | December 2018 | 200mg |
Tislelizumab | Baizean | December 2019 | 200mg |
Camrelizumab | AiRuiKa | May 2019 | 200mg |
Abbreviation: ICIs, Immune checkpoint inhibitors.